• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脓毒症和感染性休克管理的当前观点

Current perspectives in the management of sepsis and septic shock.

作者信息

Chiscano-Camón Luis, Ruiz-Sanmartin Adolf, Bajaña Ivan, Bastidas Juliana, Lopez-Martinez Rocio, Franco-Jarava Clara, Gonzalez Juan José, Larrosa Nieves, Riera Jordi, Nuvials-Casals Xavier, Ruiz-Rodríguez Juan Carlos, Ferrer Ricard

机构信息

Intensive Care Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

Shock, Organ Dysfunction and Resuscitation Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

出版信息

Front Med (Lausanne). 2024 Aug 15;11:1431791. doi: 10.3389/fmed.2024.1431791. eCollection 2024.

DOI:10.3389/fmed.2024.1431791
PMID:39211340
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11358069/
Abstract

Within patients with sepsis, there exists significant heterogeneity, and while all patients should receive conventional therapy, there are subgroups of patients who may benefit from specific therapies, often referred to as rescue therapies. Therefore, the identification of these specific patient subgroups is crucial and lays the groundwork for the application of precision medicine based on the development of targeted interventions. Over the years, efforts have been made to categorize sepsis into different subtypes based on clinical characteristics, biomarkers, or underlying mechanisms. For example, sepsis can be stratified into different phenotypes based on the predominant dysregulated host response. These phenotypes can range from hyperinflammatory states to immunosuppressive states and even mixed phenotypes. Each phenotype may require different therapeutic approaches to improve patient outcomes. Rescue strategies for septic shock may encompass various interventions, such as immunomodulatory therapies, extracorporeal support (e.g., ECMO), or therapies targeted at specific molecular or cellular pathways involved in the pathophysiology of sepsis. In recent years, there has been growing interest in precision medicine approaches to sepsis and phenotype identification. Precision medicine aims to tailor treatments to each individual patient based on their unique characteristics and disease mechanisms.

摘要

在脓毒症患者中,存在显著的异质性。虽然所有患者都应接受常规治疗,但有一部分患者亚组可能从特定治疗中获益,这些治疗通常被称为挽救治疗。因此,识别这些特定的患者亚组至关重要,并且为基于靶向干预措施发展的精准医学应用奠定了基础。多年来,人们一直在努力根据临床特征、生物标志物或潜在机制将脓毒症分为不同亚型。例如,脓毒症可根据主要失调的宿主反应分为不同表型。这些表型范围从高炎症状态到免疫抑制状态,甚至是混合表型。每种表型可能需要不同的治疗方法来改善患者预后。感染性休克的挽救策略可能包括各种干预措施,如免疫调节治疗、体外支持(如体外膜肺氧合)或针对脓毒症病理生理学中特定分子或细胞途径的治疗。近年来,人们对脓毒症的精准医学方法和表型识别越来越感兴趣。精准医学旨在根据每个患者的独特特征和疾病机制为其量身定制治疗方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f11f/11358069/7a84a760d57c/fmed-11-1431791-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f11f/11358069/7a84a760d57c/fmed-11-1431791-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f11f/11358069/7a84a760d57c/fmed-11-1431791-g0001.jpg

相似文献

1
Current perspectives in the management of sepsis and septic shock.脓毒症和感染性休克管理的当前观点
Front Med (Lausanne). 2024 Aug 15;11:1431791. doi: 10.3389/fmed.2024.1431791. eCollection 2024.
2
Sepsis Care Pathway 2019.2019年脓毒症护理路径
Qatar Med J. 2019 Nov 7;2019(2):4. doi: 10.5339/qmj.2019.qccc.4. eCollection 2019.
3
Catastrophic Disease: A Personalized Approach Based on Phenotypes and Treatable Traits.灾难性疾病:基于表型和可治疗特征的个性化方法。
Antibiotics (Basel). 2024 Feb 15;13(2):187. doi: 10.3390/antibiotics13020187.
4
Precision medicine in sepsis and septic shock: From omics to clinical tools.脓毒症和脓毒性休克中的精准医学:从组学到临床工具。
World J Crit Care Med. 2022 Jan 9;11(1):1-21. doi: 10.5492/wjccm.v11.i1.1.
5
Precision medicine in pediatric sepsis.儿科脓毒症的精准医学。
Curr Opin Pediatr. 2019 Jun;31(3):322-327. doi: 10.1097/MOP.0000000000000753.
6
Biomarkers for the Prediction and Judgement of Sepsis and Sepsis Complications: A Step towards ?用于预测和判断脓毒症及脓毒症并发症的生物标志物:迈向?
J Clin Med. 2022 Sep 29;11(19):5782. doi: 10.3390/jcm11195782.
7
Surviving Sepsis Campaign: Research Priorities for Sepsis and Septic Shock.拯救脓毒症运动:脓毒症和脓毒性休克的研究重点。
Crit Care Med. 2018 Aug;46(8):1334-1356. doi: 10.1097/CCM.0000000000003225.
8
Blood purification in sepsis and COVID-19: what´s new in cytokine and endotoxin hemoadsorption.脓毒症和新冠肺炎中的血液净化:细胞因子和内毒素血液吸附有哪些新进展。
J Anesth Analg Crit Care. 2022 Apr 4;2(1):15. doi: 10.1186/s44158-022-00043-w.
9
Identification and transcriptomic assessment of latent profile pediatric septic shock phenotypes.鉴定和转录组评估潜在的小儿脓毒性休克表型谱。
Crit Care. 2024 Jul 17;28(1):246. doi: 10.1186/s13054-024-05020-z.
10
Surviving sepsis campaign: research priorities for sepsis and septic shock.拯救脓毒症运动:脓毒症和脓毒性休克的研究重点。
Intensive Care Med. 2018 Sep;44(9):1400-1426. doi: 10.1007/s00134-018-5175-z. Epub 2018 Jul 3.

引用本文的文献

1
From cardiac injury to omics signatures: a narrative review on biomarkers in septic cardiomyopathy.从心脏损伤到组学特征:脓毒症性心肌病生物标志物的叙述性综述
Clin Exp Med. 2025 Aug 21;25(1):298. doi: 10.1007/s10238-025-01842-5.
2
Endotoxin hemoadsorption in refractory septic shock with multiorgan dysfunction and extreme endotoxin activity.内毒素血液吸附用于伴有多器官功能障碍及极高内毒素活性的难治性感染性休克。
Crit Care. 2025 May 20;29(1):206. doi: 10.1186/s13054-025-05371-1.
3
Sepsis: the evolution of molecular pathogenesis concepts and clinical management.

本文引用的文献

1
Angiotensin ii therapy in refractory septic shock: which patient can benefit most? A narrative review.难治性感染性休克中的血管紧张素 II 治疗:哪些患者获益最大?一篇叙述性综述。
J Anesth Analg Crit Care. 2024 Feb 21;4(1):13. doi: 10.1186/s44158-024-00150-w.
2
Influence of therapeutic plasma exchange treatment on short-term mortality of critically ill adult patients with sepsis-induced organ dysfunction: a systematic review and meta-analysis.治疗性血浆置换治疗对脓毒症引起的器官功能障碍的危重症成年患者短期死亡率的影响:系统评价和荟萃分析。
Crit Care. 2024 Jan 4;28(1):12. doi: 10.1186/s13054-023-04795-x.
3
Adjunctive Hemoadsorption Therapy with CytoSorb in Patients with Septic/Vasoplegic Shock: A Best Practice Consensus Statement.
脓毒症:分子发病机制概念的演变与临床管理
MedComm (2020). 2025 Feb 23;6(3):e70109. doi: 10.1002/mco2.70109. eCollection 2025 Mar.
4
Upregulation of CRISP3 and its clinical values in adult sepsis: a comprehensive analysis based on microarrays and a two-retrospective-cohort study.CRISP3在成人脓毒症中的上调及其临床价值:基于微阵列和两项回顾性队列研究的综合分析
Front Immunol. 2024 Nov 18;15:1492538. doi: 10.3389/fimmu.2024.1492538. eCollection 2024.
细胞吸附剂(CytoSorb)辅助血液吸附疗法治疗脓毒症/血管麻痹性休克患者:最佳实践共识声明
J Clin Med. 2023 Nov 21;12(23):7199. doi: 10.3390/jcm12237199.
4
Endotoxin activity trend and multi-organ dysfunction in critically ill patients with septic shock, who received Polymyxin-B hemadsorption: A multicenter, prospective, observational study.多黏菌素 B 血液灌流治疗脓毒性休克患者:一项多中心、前瞻性、观察性研究。
Artif Organs. 2023 Aug;47(8):1361-1370. doi: 10.1111/aor.14534. Epub 2023 Apr 27.
5
Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1β.发现一种选择性的、具有生物活性的人白细胞介素-1β小分子拮抗剂。
Nat Commun. 2023 Sep 7;14(1):5497. doi: 10.1038/s41467-023-41190-0.
6
Use of Biomarkers to Improve 28-Day Mortality Stratification in Patients with Sepsis and SOFA ≤ 6.使用生物标志物改善脓毒症且序贯器官衰竭评估(SOFA)评分≤6分患者的28天死亡率分层
Biomedicines. 2023 Jul 30;11(8):2149. doi: 10.3390/biomedicines11082149.
7
Mortality Risk Prediction in Abdominal Septic Shock Treated with Polymyxin-B Hemoperfusion: A Retrospective Cohort Study.多粘菌素B血液灌流治疗腹部感染性休克的死亡风险预测:一项回顾性队列研究。
J Pers Med. 2023 Jun 21;13(7):1023. doi: 10.3390/jpm13071023.
8
Potential survival benefit and early recovery from organ dysfunction with polymyxin B hemoperfusion: perspectives from a real-world big data analysis and the supporting mechanisms of action.多粘菌素B血液灌流对潜在生存获益及器官功能障碍早期恢复的影响:基于真实世界大数据分析的观点及支持性作用机制
J Anesth Analg Crit Care. 2022 Jun 20;2(1):27. doi: 10.1186/s44158-022-00056-5.
9
Blood purification in sepsis and COVID-19: what´s new in cytokine and endotoxin hemoadsorption.脓毒症和新冠肺炎中的血液净化:细胞因子和内毒素血液吸附有哪些新进展。
J Anesth Analg Crit Care. 2022 Apr 4;2(1):15. doi: 10.1186/s44158-022-00043-w.
10
Targeted therapy using polymyxin B hemadsorption in patients with sepsis: a post-hoc analysis of the JSEPTIC-DIC study and the EUPHRATES trial.使用多黏菌素 B 血液吸附治疗脓毒症患者的靶向治疗:JSEPTIC-DIC 研究和 EUPHRATES 试验的事后分析。
Crit Care. 2023 Jun 21;27(1):245. doi: 10.1186/s13054-023-04533-3.